• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Amgen-Onyx File for Full Approval for Kyprolis in MM

Article

Kyprlois is currently approval for use in multiple myeloma patients who have progressed on 2 prior therapies.

Amgen and its subsidiary Onyx Pharmaceuticals have submitted filings for their multiple myeloma drug Kyprolis (carfilzomib) on both sides of the Atlantic. The companies are seeking approval to market their drug for the treatment of patents with relapsed multiple myeloma who have received at least one prior therapy.

In the US, Kyprolis is already cleared under accelerated approval for use in patients with multiple myeloma who have already received at least two other treatments and whose disease has progressed; a supplemental New Drug Application has now been filed to support the conversion of this to full approval and expand target population.

In the European Union, Kyprolis has received orphan drug designation and the marketing application has been granted accelerated assessment.

Complete report on PharmaTimes:

http://bit.ly/1Dbog3O

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.